In an ICU patient with chronic kidney disease who has developed acute kidney injury, should alpha‑keto analogue (keto‑acid) supplementation be continued?

Discontinue Alpha-Keto Analogues in ICU Patients with CKD on AKI

In an ICU patient with chronic kidney disease who has developed acute kidney injury, alpha-keto analogue supplementation should be discontinued and replaced with adequate protein intake (1.3-1.7 g/kg/day depending on kidney replacement therapy status).

Rationale Based on Current Guidelines

The 2024 ESPEN guideline explicitly addresses this clinical scenario and provides clear direction 1. The fundamental principle is that acute/critical illness fundamentally changes nutritional requirements, overriding the conservative protein management approach used in stable CKD patients.

Key Clinical Decision Points:

For your ICU patient with CKD + AKI:

• If NOT on kidney replacement therapy (KRT): Start with 1.0 g/kg/day protein, gradually increasing to 1.3 g/kg/day if tolerated 1

• If on conventional intermittent KRT: Provide 1.3-1.5 g/kg/day protein 1

• If on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT): Provide 1.5-1.7 g/kg/day protein 1

Why Alpha-Keto Analogues Are Inappropriate in This Setting:

1. Catabolic State Dominates: ICU patients with AKI experience severe protein catabolism that is not influenced by protein intake restriction 1. The guideline explicitly states that "protein catabolism in patients with AKI is only quite partially influenced by protein intake, i.e. lowering protein intake does not influence the protein catabolic rate" 1.

2. Protein Restriction Worsens Outcomes: The 2024 ESPEN guideline provides a Grade A recommendation (strong consensus 96%) that "protein prescription shall not be reduced in order to avoid or delay KRT start in critically ill patients with AKI, AKI on CKD, or CKD with KF" 1.

3. Previous Low-Protein Regimens Must Be Stopped: The guideline explicitly states with 100% strong consensus that "CKD patients previously maintained on controlled protein intake (the so-called 'low protein diet') should not be maintained on this regimen during hospitalization if acute illness is the reason for hospitalization" 1.

4. Alpha-Keto Analogues Are Designed for Stable Outpatients: All research evidence supporting keto-analogues involves non-critically ill, stable CKD patients following low or very-low protein diets 2, 3, 4, 5, 6. None of these studies included ICU patients with acute illness.

Practical Implementation:

Immediate Actions:

• Stop alpha-keto analogue supplementation
• Calculate protein needs based on pre-hospitalization or usual body weight (NOT actual body weight due to fluid overload) 1
• Use concentrated renal formulas (70-80 g protein/L) if using enteral nutrition to minimize fluid overload 1
• Consider parenteral amino acid supplementation if enteral route cannot meet protein goals 1

Monitor closely:

• Trace elements (selenium, zinc, copper) - these require supplementation during critical illness and KRT due to increased losses 1
• Avoid using elevated BUN as a reason to reduce protein intake 1

Critical Pitfall to Avoid:

Do not attempt to delay KRT initiation by restricting protein. This outdated approach worsens nitrogen balance and outcomes without meaningfully affecting the need for dialysis 1. The meta-analysis cited in the guideline found no outcome difference between early versus late KRT timing 1, so protein prescription should be guided by the patient's catabolic state, not by attempts to avoid dialysis.

Exception (Not Applicable to Your ICU Patient):

The only scenario where moderately restricted protein with keto-analogues might be considered is in metabolically stable, non-catabolic patients with isolated AKI (e.g., contrast-induced, drug-induced) who are NOT critically ill and NOT in the ICU 1. This clearly does not apply to your clinical scenario.

1